TABLE 3.

Occurrence of discontinuation of Obeticholic acid

Characteristic	N = 100
OCA discontinuation, n	22 (22%)
Time of OCA discontinuation
Before 6 months	7 (32%)
Between 6 and 12 months	15 (68%)
Reason for OCA discontinuation
Pruritus	10 (45.5%)
Hepatic severe adverse events a	9 (40.9%)
Anaemia	1 (4.5%)
Complication after hip fracture	1 (4.5%)
COVID‐19	1 (4.5%)

^a Includes patients experiencing on‐treatment death after TIPS placement for refractory bleeding from portal hypertensive gastropathy (1, 4.5%).